TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed high-risk breast cancer~  * Stage I-III disease~* Has undergone definitive surgery with or without radiotherapy~  * Completely resected disease~* Bone marrow aspirate positive for occult tumor cells, defined as ≥ 10 occult tumor cells/mL by IHC and flow cytometry~  * If the patient received either no adjuvant therapy or hormonal therapy alone, the aspiration may have been performed at diagnosis as part of the large micrometastasis study at UCSF, or following diagnosis if the patient underwent initial surgery elsewhere (or underwent surgery following neoadjuvant therapy for breast cancer)~ * If the patient received adjuvant chemotherapy, the aspiration must have been performed ≥ 3 weeks after completion of chemotherapy~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* ECOG performance status 0-1~* WBC count normal (3.4-10 x 10\^9/L)~* Hemoglobin \> 9.0 g/dL~* Platelet count normal (140-450 x 10\^9/L)~* ANC normal (1.8-6.8 x 10\^9/L)~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 1.5 times ULN~* AST and ALT ≤ 2.5 times ULN~* TSH and T4 levels normal~* LVEF \> 50%~* Systolic BP \< 140 mm Hg and diastolic BP \< 90 mm Hg~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of HIV infection~* No concurrent severe illness that would likely preclude study compliance~* No other malignancy within the past 5 years except basal cell carcinoma of the skin~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior sunitinib malate~* Prior adjuvant chemotherapy, including trastuzumab (Herceptin®), allowed provided it was completed within the past 6 months~* Prior surgery following neoadjuvant chemotherapy or hormonal therapy allowed~* No concurrent potent CYP3A4 inducers~* No concurrent trastuzumab~* Concurrent hormonal therapy or radiotherapy allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- sunitinib (Type: EXPERIMENTAL): Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically documented primary brain tumor for which surgical resection is indicated.~* Age 18 years and older.~* ECOG Performance status less than or equal to 2.~* Laboratory values as follows:~Leukocytes greater than or equal to 3,000. ANC greater than or equal to 1,500. Platelets greater than or equal to 100,000. Total Bilirubin WNL. AST/ALT less than or equal to 2.5 times ULN. Creatinine WNL. or Creatinine Clearance greater than or equal to 60ml/min/1.73m2 if SCr above institutional normal.~-Ability to provide informed consent or consent from a Legally Authorized Representative.~Exclusion Criteria:~* Receipt of an investigational agent within 30 days.~* Allergy to ALA or similar compounds.~* Personal or family history of porphyria.~* Uncontrolled intercurrent illness.~* Inability to comply with the protocol.~* Pregnancy, breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminolevulinic Acid (AL) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bariatric Surgery on Brain Insulin Sensitivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 75 years~* planned bariatric surgery (laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy)~* stable medication 10 weeks before begin of the study~Exclusion Criteria:~* persons who wear non-removable metal parts in or on the body.~* persons with reduced temperature sensitivity and / or increased sensitivity to heating of the body~* cardiovascular disease can not be ruled out, e.g. manifest coronary heart disease, heart failure greater than NYHA 2, previous heart attack, stroke condition~* persons with hearing impairment or increased sensitivity to loud noises~* people with claustrophobia~* minors or non-consenting subjects are also excluded~* subjects with an operation less than 3 months~* neurological and psychiatric disorders~* subjects with hemoglobin Hb \<11 g / dl~* hypersensitivity to any of the substances used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bariatric surgery (Type: EXPERIMENTAL): Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DLBS1033 for the Treatment of Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with age of 18-75 years .~* Has been diagnosed with acute ischemic stroke clinically confirmed by CT scan.~* Modified National Institutes of Health Stroke Scale (mNIHSS) score \>= 5.~* Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.~* Able to take oral medication.~Exclusion Criteria:~* For females of childbearing potential: pregnancy and lactation period.~* History of or current hemorrhagic stroke (within the last 3 months).~* Transient ischemic stroke (TIA).~* Patients with seizure at the onset of stroke.~* History of serious head injury within the last 3 months.~* History of major surgery within the last 3 months.~* Serious cardiovascular conditions, such as myocardial infarction, CHF grade III and IV (NYHA classification), aorta dissection, and atrial fibrillation within the last 6 months.~* Presence of severe renal or hepatic dysfunction~* Presence of acute or chronic infections.~* Thrombocytopenia (thrombocytes level \< 150.000/ul).~* Patients with higher risks of bleeding.~* Uncontrolled hypertension (systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg).~* Random plasma glucose \>= 200 mg/dL.~* Current or regular use of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.~* Hypersensitive to the investigational product(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
- DLBS1033 Group (Type: EXPERIMENTAL): DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (Mothers):~* The patient must have a documented laronidase deficiency with a fibroblast, plasma, serum, leukocyte, or dried blood spot laronidase enzyme activity assay.~* Be pregnant, planning to breastfeed post-partum, and receiving Aldurazyme (laronidase) therapy while breastfeeding.~* Provide signed, written informed consent prior to any protocol-related procedures. Consent of a legally authorized guardian(s) is (are) required for mothers younger than 18 years of age. If a mother is under 18 years old and can understand the consent, written informed consent is required from both the mother and the authorized guardian(s).~* Provide signed, written informed consent for their infants to participate as study patients. If a mother is younger than 18 years of age, consent for mother and infant will be obtained from the legal guardian.~Exclusion Criteria (Mothers and Infants):~* Have a medical condition, serious intercurrent illness, or other extenuating circumstance that may interfere with study compliance, including all prescribed evaluations and follow-up activities.~* Have received an investigational drug within 30 days prior to study enrollment.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laronidase (Type: EXPERIMENTAL): Mothers treated with laronidase who intended to breastfeed their infants while receiving laronidase and their infants who were breastfeed while the mothers were receiving laronidase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sleep Patterns to Determine Predictive Markers Due to Cardiovascular Disease in Elderly Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects living at Masonic Homes/Acacia Creek Retirement Community who use a Sleep Number® bed and are cognitively able to consent on their own accord.~Exclusion Criteria:~* Subjects who do not have a Sleep Number® bed.~* Subjects without an internet connection to transmit nightly SleepIQ® data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose-adjusted EPOCH-R in MYC Positive DLBCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated MYC positive diffuse large B-cell lymphoma~* Age range 18-70 years old~* Eastern Cooperative Oncology Group performance status 0-2~* Life expectancy of more than 3 months~* Adequate organ function~Exclusion Criteria:~* Primary or secondary central nervous system involvement~* Previous serious cardiac disease~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Pregnant or lactating women~* Serious uncontrolled diseases and intercurrent infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DA-EPOCH-R (Type: EXPERIMENTAL): rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's Disease~* Modified Hoehn \& Yahr Stage \< III~* Diagnosis of Parkinson's Disease made within past 3 years•~* Ability to complete questionnaires~* Willingness to go off parkinsonian medication for 12 hours prior to baseline and 56-week assessments~Exclusion Criteria:~* Other major diseases of the central nervous system~* History of stroke~* Use of antipsychotic neuroleptic medication within the last 6 months~* Symptomatic (secondary) parkinsonism~* Atypical parkinsonian variants~* Unstable medical or psychiatric illness~* Known kidney disease~* History of stereotactic brain surgery~* Significant cognitive impairment~* Inability to safely tolerate 8 ounces of water twice daily associated with the study medication~* Unable to avoid regular use of medications containing magnesium~* Treatment with another investigational drug within the last 30 days that may interfere with the study medication~* Pregnancy or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hydrogen tablets (Type: EXPERIMENTAL): The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
- Placebo tablets (Type: PLACEBO_COMPARATOR): effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria (Double-Blind Part):~* Women of non-childbearing potential and men, aged 21-80 years~* Willingness and ability to complete all aspects of the study; participant should be capable of completing assessments either alone or with help of a caregiver~* Diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) ALS according to the El Escorial World Federation of Neurology revised research diagnostic criteria~* Less than 3 years since symptom onset~* Forced vital capacity (FVC) \>50% predicted measured within 30 days of screening~* If subject is taking approved ALS treatments (riluzole and/or edaravone), doses must be stable for ≥2 months prior to screening and subject is expected to stay on a stable regimen throughout the study~Key Exclusion Criteria (Double-Blind Part):~* History of a clinically significant non-ALS neurologic disorder (other than frontal temporal lobe dementia), including, but not limited to, muscular dystrophy, spinal stenosis, peripheral neuropathy, inherited neuropathies, AD, Parkinson's disease, Lewy body dementia, vascular dementia, Huntington's disease, epilepsy, stroke, multiple sclerosis, brain tumor, or brain infection or abscess~* Unstable or poorly controlled comorbid disease process of any organ system currently requiring active treatment or likely to require treatment adjustment during the study~Key Inclusion Criteria (Open-Label Extension):~* Successful completion of both periods of the the double-blind, crossover part of the study~* Continued diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) ALS according to the El Escorial World Federation of Neurology revised research diagnostic criteria~Key Exclusion Criteria (Open-Label Extension):~* Presence of laboratory abnormalities, physical examination findings, or AEs determined to be clinically significant by the investigator from the double-blind part of the study that have not resolved by the final follow-up visit as part of the double-blind study period~* New diagnosis of clinically significant neurological disorder (other than frontal temporal lobe dementia)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DNL747 First, Placebo Second (Type: EXPERIMENTAL): None
- Placebo First, DNL747 Second (Type: EXPERIMENTAL): None
- Open-Label Extension (Type: EXPERIMENTAL): Conducted in the Netherlands only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Urinary Incontinence for at least 3 months prior to Screening as a result of Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.~* Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or below which occurred at least 6 months prior to Screening.~* Subjects with Multiple Sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of MS for at least 3 months prior to Screening.~* Subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects.~* Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate bladder emptying.~* An average of at least two episodes per day of Urinary Incontinence recorded on the screening bladder diary.~Key Exclusion Criteria:~* Any current condition (other than NDO) that may impact on bladder function.~* Previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of SCI.~* Any condition that will prevent cystoscopic treatment administration or CIC usage, e.g. urethral strictures.~* Current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to Screening.~* BTX-A treatment within 9 months prior to Screening for any urological condition (e.g. detrusor or urethral sphincter treatments).~* Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to Screening. Any implanted neuromodulation device must be switched off at least 4 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 600 U Dysport® Group (Type: EXPERIMENTAL): None
- 600 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None
- 800 U Dysport® Group (Type: EXPERIMENTAL): None
- 800 U Dysport® Placebo Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age ≥ 18 jr~* WHO performance status 0-2~* Last radiation treatment ≥ 6 month ago radiotherapy with curative intention and \> 55 Gy. The affected part of the jaw must be in the target volume area of the radiotherapy field.~* Local recurrence must be ruled out~* Necrosis of the jaw with at least one of the following symptoms for over 3 month present:~  * Bone exposition which measures at least 1 cm~ * Evident bone lesions at radiologic evaluation (panorex) that fits the diagnosis ORN.~ * Non-healing extraction socket~Exclusion Criteria:~* Former HBO treatment~* Contra indication for HBO treatment (pneumothorax)~* Bisphosphonate treatment in the medical history~* reirradiation in the medical history~* Osteosynthesis material in the affected area~* Distant metastasis~* Primary or recurrent tumor in the affected area~* Malignancies elsewhere

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery (Type: NO_INTERVENTION): This is the standard arm. Surgery without hyperbaric oxygen treatment
- Hyperbaric oxygen therapy with surgery (Type: EXPERIMENTAL): Intervention arm. Hyperbaric oxygen therapy with surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STAND: iSchemic sTroke evAluated at Bed Side With ultrasouND

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Patient over 18 years of age~* acute ischemic stroke or transient ischemic attack~* symptoms onset \< 48 hours~* Absence of homolateral or downstream intracranial stenosis or M1 occlusion~* Verticalization authorized by the referent clinician.~* Rankin's score before AIC/AIT ≤ 2~* Non-opposition to participation in the study~Criteria for inclusion of cases~- Carotid stenosis of more than 50% NASCET or an occlusion~Criteria for including witnesses - Absence of carotid stenosis greater than 50% NASCET or occlusion~Criteria for non-inclusion~- Disrupted vigilance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stenosis (Type: None): Patients with stenosis
- No stenosis (Type: None): Patients without stenosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues